Intra-Cellular Therapies (NASDAQ:ITCI)’s share price rose 4% during trading on Tuesday after Guggenheim raised their price target on the stock from $95.00 to $104.00, MarketBeat reports. Guggenheim currently has a buy rating on the stock. Intra-Cellular Therapies traded as high as $41.39 and last traded at $38.51, with a volume of 973,049 shares traded. The […]
